Skip to main content
main-content

Genitourinary cancers

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

medwireNews editor's pick

Neoadjuvant pembrolizumab ‘worthwhile’ for some invasive bladder cancers

IV drip_patient's hand

Neoadjuvant pembrolizumab therapy results in an “impressively high” pathologic complete response rate among patients with programmed cell death ligand 1-positive muscle-invasive bladder carcinoma, researchers say.

medwireNews@ESMO2018

Genitourinary cancers coverage at the ESMO Congress 2018

Munich
Expert opinion

Bipolar androgen therapy: Progress and future directions

Bipolar androgen therapy: Progress and future directions

Michael Schweizer (University of Washington, Seattle, USA) outlines a new therapy that utilizes both androgen deprivation and administration, which may potentially have benefit for prostate cancer patients.

Expert opinion

Urinary biomarkers in the management of prostate cancer

Urinary biomarkers in the management of prostate cancer

Non-invasive biomarkers have the potential to guide and improve prostate cancer management in many ways. Maria Frantzi, Agnieszka Latosinska, and Harald Mischak (Mosaiques Diagnostics GmbH, Germany) outline some promising markers and what is needed to implement them in the clinic.

medwireNews editor's pick

Equivalent outcomes for robot-assisted and open radical prostatectomy

Surgical robot

Robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy have similar functional outcomes at 2 years, according to phase III study findings in The Lancet Oncology.

19-11-2018 | Head and neck cancers | ESMO 2018 | Video

Experts reflect on their highlights from ESMO 2018

Hisham Mehanna, Ricardo Alvarez and Massimo Christofanilli, and Thomas Seufferlein discuss their ESMO 2018 highlights in head & neck, breast, and gastrointestinal cancer, respectively (7:42).

15-11-2018 | Prostate cancer | Podcast | Audio

Researcher comment: COMPARE study

Hashim Ahmed takes us through the COMPARE study – presented at NCRI 2018 – which showed that men with localized prostate cancer are willing to make accept lower survival odds for a better quality of life. He outlines the key findings, the implications of the results for physicians, and the next steps for research (5:36).

Click here for the accompanying news story.

30-10-2018 | Colorectal cancer | ESMO 2018 | Video

Nivolumab plus low-dose ipilimumab promising for treatment-naïve MSI-high mCRC

Heinz-Josef Lenz outlines the results of CheckMate-142 study investigating combination immunotherapy in the first-line treatment of patients with MSI-high metastatic colorectal cancer, and discusses the unmet needs of those with MSI-low tumors (5:58).

15-11-2018 | Renal cell carcinoma | News

Genomic annotation improves MSKCC risk model for renal carcinoma

Adding the mutation status of three genes linked to renal cell carcinoma improves the prognostic value of the Memorial Sloan Kettering Cancer Center risk model for patients receiving tyrosine kinase inhibitors for metastatic disease, research shows.

12-11-2018 | Bladder cancer | Highlight | News

Neoadjuvant pembrolizumab ‘worthwhile’ for some invasive bladder cancers

Neoadjuvant pembrolizumab therapy results in an “impressively high” pathologic complete response rate among patients with programmed cell death ligand 1-positive muscle-invasive bladder carcinoma, researchers say.

09-11-2018 | Prostate cancer | News

Prostate cancer patients willing to make trade-offs between survival, side effects

Men with a new diagnosis of nonmetastatic prostate cancer say they would accept small reductions in survival odds if that meant fewer side effects and an improved quality of life, suggests the COMPARE study.

Themed collections

31-05-2018 | Genitourinary cancers | Themed collection | Collection

Best of JCO™ 2018: Genitourinary Cancer Edition

Here we present free-to-access, full-text, original research articles published in Journal of Clinical Oncology that are some of the most-accessed in the area of genitourinary cancers. The articles cover a range of topics including therapies for metastatic castration-resistant prostate cancer and bladder cancer.

Journal articles and book chapters

29-06-2018 | Castration-resistant prostate cancer | Article

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Hussain M et al. N Engl J Med 2018; 378(26): 2465-2474. doi:10.1056/NEJMoa1800536

28-06-2018 | PARP inhibitors | Article

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

Ashworth A. Lord CJ. Nat Rev Clin Oncol 2018. doi:10.1038/s41571-018-0055-6

14-06-2018 | Renal cell carcinoma | Article

An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma

Grünwald V et al. Nat Rev Urol 2018. doi:10.1038/s41585-018-0034-9.

05-06-2018 | Prostate cancer | Article

Statin use and time to progression in men on active surveillance for prostate cancer

Jayalath VH et al. Prostate Cancer Prostatic Dis 2018. doi:10.1038/s41391-018-0053-x

05-06-2018 | Radiotherapy | Article

Safety of combining radiotherapy with immune-checkpoint inhibition

Hwang WL et al. Nat Rev Clin Oncol 2018. doi: 10.1038/s41571-018-0046-7

04-06-2018 | Renal cell carcinoma | Article

Epigenetics in renal cell cancer: mechanisms and clinical applications

Joosten SC et al. Nat Rev Urol 2018. doi:10.1038/s41585-018-0023-z

27-05-2018 | Prostate cancer | Article

Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms in Predicting Adverse Pathology in Prostate Cancer

Rayn KN et al. J Urol 2018; pii: S0022-5347(18)43271-5. doi:10.1016/j.juro.2018.05.094

Images and illustrations

12-04-2018 | Prostate cancer | Images and illustration slides | Collection

Prostate cancer imaging

This downloadable powerpoint slide set presents an overview of the imaging techniques used to assess prostate cancer from initial diagnosis and staging, to evaluation of residual or recurrent disease after treatment. These slides can be used for reference purposes or for inclusion in one’s own slide sets. Source: Vargas HA et al. Prostate Cancer Imaging. In: Bach Am, Zhang J, eds. Atlas of Genitourinary Oncological Imaging. Springer New York.

Our Editorial Board advisor

Axel S Merseburger MD

Dr Merseburger is currently Professor and Chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany, having previously served as Vice Chairman of the Department of Urologic Oncology and Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Dr Merseburger’s key areas of interest are renal cell carcinoma, prostate cancer and transitional cell carcinoma, with special attention given to novel markers and prognostic factors. He is a principal investigator in German Phase II and III trials.

image credits